​

Evommune Stock (NYSE:EVMN)

RevenueFinancialsChart
Evommune by TradingView

Previous Close

$17.91

52W Range

$13.88 - $24.03

50D Avg

$18.94

200D Avg

$18.94

Market Cap

$226.41M

Avg Vol (3M)

$220.99K

Beta

-

Div Yield

-

EVMN Company Profile

Evommune, Inc. operates as a clinical-stage biotechnology company in the United States. It develops therapies that target key drivers of chronic inflammatory diseases, with initial clinical development programs focusing on chronic spontaneous urticaria, atopic dermatitis, and ulcerative colitis. Its products includes EVO756 for the treatment of CSU and AD; and EVO301 for the treatment of AD and UC. The company was incorporated in 2020 and is based in Palo Alto, California.

Show More

Industry

Biotechnology

Sector

Healthcare

Exchange

NYSE

ADR

-

Country

US

Employees

45

IPO Date

Nov 06, 2025

Website

EVMN Performance

EVMN Financial Summary

Dec 24Dec 23
Revenue$7.00M$5.00M
Operating Income$-70.01M$-37.85M
Net Income$-66.81M$-34.05M
EBITDA$-65.49M$-32.99M
Basic EPS$-2.27$-1.13
Diluted EPS$-2.27$-1.13

Fiscal year ends in Dec 24 | Currency in USD

Peer Comparison

TickerCompany
GLPGGalapagos N.V.
ARTVArtiva Biotherapeutics, Inc.
EYPTEyePoint Pharmaceuticals, Inc.
OABIOmniAb, Inc.
CLYMClimb Bio, Inc.
ZYMEZymeworks Inc.
CDXSCodexis, Inc.
LGNDLigand Pharmaceuticals Incorporated
FTREFortrea Holdings Inc.
KPTIKaryopharm Therapeutics Inc.